Quest Diagnostics Incorporated (NYSE: DGX) Stock Competitors & Peer Comparison
See DGX's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for DGX and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DGX | $246.65 | +3.68% | 27.3B | 24.39 | $10.14 | +1.34% |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.69% |
| TMO | $647.89 | +5.67% | 238.4B | 27.70 | $23.16 | +0.29% |
| DHR | $209.36 | +3.01% | 147.1B | 26.23 | $7.98 | +0.69% |
| NTRA | $349.44 | +2.24% | 50.2B | -265.74 | -$1.32 | N/A |
| IQV | $270.94 | +1.98% | 44.4B | 22.22 | $12.13 | N/A |
| A | $153.58 | +4.62% | 42.4B | 25.85 | $5.81 | +0.67% |
| IDXX | $519.83 | +2.02% | 40.3B | 35.92 | $14.22 | N/A |
| ILMN | $228.00 | +9.51% | 33.6B | 44.19 | $5.03 | N/A |
| WAT | $420.59 | +2.58% | 31.2B | 30.49 | $13.68 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
DGX vs DHR-PB Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, DGX's ROE is +0.14%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, DGX is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for DGX.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
DGX vs TMO Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, TMO has a market cap of 238.4B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while TMO trades at $647.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas TMO's P/E ratio is 27.70. In terms of profitability, DGX's ROE is +0.14%, compared to TMO's ROE of +0.13%. Regarding short-term risk, DGX is less volatile compared to TMO. This indicates lower risk in terms of short-term price fluctuations for DGX.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
DGX vs DHR Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, DHR has a market cap of 147.1B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while DHR trades at $209.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas DHR's P/E ratio is 26.23. In terms of profitability, DGX's ROE is +0.14%, compared to DHR's ROE of +0.08%. Regarding short-term risk, DGX is less volatile compared to DHR. This indicates lower risk in terms of short-term price fluctuations for DGX.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
DGX vs NTRA Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, NTRA has a market cap of 50.2B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while NTRA trades at $349.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas NTRA's P/E ratio is -265.74. In terms of profitability, DGX's ROE is +0.14%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, DGX is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for DGX.Check NTRA's competition here
IQVIA Holdings Inc. (NYSE: IQV)
DGX vs IQV Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, IQV has a market cap of 44.4B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while IQV trades at $270.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas IQV's P/E ratio is 22.22. In terms of profitability, DGX's ROE is +0.14%, compared to IQV's ROE of +0.22%. Regarding short-term risk, DGX is less volatile compared to IQV. This indicates lower risk in terms of short-term price fluctuations for DGX.Check IQV's competition here
Agilent Technologies, Inc. (NYSE: A)
DGX vs A Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, A has a market cap of 42.4B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while A trades at $153.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas A's P/E ratio is 25.85. In terms of profitability, DGX's ROE is +0.14%, compared to A's ROE of +0.20%. Regarding short-term risk, DGX is less volatile compared to A. This indicates lower risk in terms of short-term price fluctuations for DGX.Check A's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
DGX vs IDXX Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, IDXX has a market cap of 40.3B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while IDXX trades at $519.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas IDXX's P/E ratio is 35.92. In terms of profitability, DGX's ROE is +0.14%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, DGX is less volatile compared to IDXX. This indicates lower risk in terms of short-term price fluctuations for DGX.Check IDXX's competition here
Illumina, Inc. (NASDAQ: ILMN)
DGX vs ILMN Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, ILMN has a market cap of 33.6B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while ILMN trades at $228.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas ILMN's P/E ratio is 44.19. In terms of profitability, DGX's ROE is +0.14%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, DGX is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for DGX.Check ILMN's competition here
Waters Corporation (NYSE: WAT)
DGX vs WAT Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, WAT has a market cap of 31.2B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while WAT trades at $420.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas WAT's P/E ratio is 30.49. In terms of profitability, DGX's ROE is +0.14%, compared to WAT's ROE of +0.02%. Regarding short-term risk, DGX is less volatile compared to WAT. This indicates lower risk in terms of short-term price fluctuations for DGX.Check WAT's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
DGX vs MTD Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, MTD has a market cap of 26.9B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while MTD trades at $1,376.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas MTD's P/E ratio is 30.58. In terms of profitability, DGX's ROE is +0.14%, compared to MTD's ROE of -12.00%. Regarding short-term risk, DGX is less volatile compared to MTD. This indicates lower risk in terms of short-term price fluctuations for DGX.Check MTD's competition here
Labcorp Holdings Inc. (NYSE: LH)
DGX vs LH Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, LH has a market cap of 25.9B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while LH trades at $324.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas LH's P/E ratio is 18.72. In terms of profitability, DGX's ROE is +0.14%, compared to LH's ROE of +0.12%. Regarding short-term risk, DGX is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for DGX.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
DGX vs GH Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, GH has a market cap of 23.6B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while GH trades at $176.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas GH's P/E ratio is -50.33. In terms of profitability, DGX's ROE is +0.14%, compared to GH's ROE of +2.11%. Regarding short-term risk, DGX is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for DGX.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
DGX vs EXAS Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas EXAS's P/E ratio is -95.37. In terms of profitability, DGX's ROE is +0.14%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, DGX is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for DGX.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
DGX vs MEDP Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, MEDP has a market cap of 17.3B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while MEDP trades at $618.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas MEDP's P/E ratio is 36.37. In terms of profitability, DGX's ROE is +0.14%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, DGX is less volatile compared to MEDP. This indicates lower risk in terms of short-term price fluctuations for DGX.Check MEDP's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
DGX vs ILMNV Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas ILMNV's P/E ratio is N/A. In terms of profitability, DGX's ROE is +0.14%, compared to ILMNV's ROE of N/A. Regarding short-term risk, DGX is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for DGX.Check ILMNV's competition here
Revvity, Inc. (NYSE: RVTY)
DGX vs RVTY Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, RVTY has a market cap of 15.6B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while RVTY trades at $145.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas RVTY's P/E ratio is 26.19. In terms of profitability, DGX's ROE is +0.14%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, DGX is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for DGX.Check RVTY's competition here
PerkinElmer, Inc. (NYSE: PKI)
DGX vs PKI Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas PKI's P/E ratio is 41.45. In terms of profitability, DGX's ROE is +0.14%, compared to PKI's ROE of +0.03%. Regarding short-term risk, DGX is less volatile compared to PKI. This indicates lower risk in terms of short-term price fluctuations for DGX.Check PKI's competition here
ICON Public Limited Company (NASDAQ: ICLR)
DGX vs ICLR Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, ICLR has a market cap of 13.2B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while ICLR trades at $174.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas ICLR's P/E ratio is 14.07. In terms of profitability, DGX's ROE is +0.14%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, DGX is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for DGX.Check ICLR's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
DGX vs CRL Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, CRL has a market cap of 13.1B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while CRL trades at $279.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas CRL's P/E ratio is 27.53. In terms of profitability, DGX's ROE is +0.14%, compared to CRL's ROE of -0.08%. Regarding short-term risk, DGX is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for DGX.Check CRL's competition here
Qiagen N.V. (NYSE: QGEN)
DGX vs QGEN Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, QGEN has a market cap of 8.8B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while QGEN trades at $43.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas QGEN's P/E ratio is 17.55. In terms of profitability, DGX's ROE is +0.14%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, DGX is less volatile compared to QGEN. This indicates lower risk in terms of short-term price fluctuations for DGX.Check QGEN's competition here
RadNet, Inc. (NASDAQ: RDNT)
DGX vs RDNT Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, RDNT has a market cap of 6.1B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while RDNT trades at $77.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas RDNT's P/E ratio is 167.65. In terms of profitability, DGX's ROE is +0.14%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, DGX is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for DGX.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
DGX vs SHC Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, SHC has a market cap of 5.4B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while SHC trades at $19.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas SHC's P/E ratio is 19.77. In terms of profitability, DGX's ROE is +0.14%, compared to SHC's ROE of +0.27%. Regarding short-term risk, DGX is less volatile compared to SHC. This indicates lower risk in terms of short-term price fluctuations for DGX.Check SHC's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
DGX vs BLLN Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, BLLN has a market cap of 4.8B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while BLLN trades at $105.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas BLLN's P/E ratio is 148.96. In terms of profitability, DGX's ROE is +0.14%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, DGX is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for DGX.Check BLLN's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
DGX vs SYNH Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas SYNH's P/E ratio is 61.40. In terms of profitability, DGX's ROE is +0.14%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, DGX is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for DGX.Check SYNH's competition here
GRAIL Inc. (NASDAQ: GRAL)
DGX vs GRAL Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, GRAL has a market cap of 3.3B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while GRAL trades at $76.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas GRAL's P/E ratio is -7.78. In terms of profitability, DGX's ROE is +0.14%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, DGX is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for DGX.Check GRAL's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
DGX vs OLK Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas OLK's P/E ratio is -96.59. In terms of profitability, DGX's ROE is +0.14%, compared to OLK's ROE of -0.07%. Regarding short-term risk, DGX is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for DGX.Check OLK's competition here
Veracyte, Inc. (NASDAQ: VCYT)
DGX vs VCYT Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, VCYT has a market cap of 3.2B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while VCYT trades at $40.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas VCYT's P/E ratio is 20.07. In terms of profitability, DGX's ROE is +0.14%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, DGX is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for DGX.Check VCYT's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
DGX vs WGS Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, WGS has a market cap of 2.8B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while WGS trades at $98.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas WGS's P/E ratio is 262.89. In terms of profitability, DGX's ROE is +0.14%, compared to WGS's ROE of -0.39%. Regarding short-term risk, DGX is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for DGX.Check WGS's competition here
CareDx, Inc (NASDAQ: CDNA)
DGX vs CDNA Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, CDNA has a market cap of 2.7B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while CDNA trades at $54.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas CDNA's P/E ratio is 62.67. In terms of profitability, DGX's ROE is +0.14%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, DGX is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for DGX.Check CDNA's competition here
Personalis, Inc. (NASDAQ: PSNL)
DGX vs PSNL Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while PSNL trades at $16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas PSNL's P/E ratio is -14.77. In terms of profitability, DGX's ROE is +0.14%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, DGX is less volatile compared to PSNL. This indicates lower risk in terms of short-term price fluctuations for DGX.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
DGX vs OPK Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while OPK trades at $1.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas OPK's P/E ratio is -5.81. In terms of profitability, DGX's ROE is +0.14%, compared to OPK's ROE of -0.06%. Regarding short-term risk, DGX is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for DGX.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
DGX vs CSTL Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, CSTL has a market cap of 1.1B. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while CSTL trades at $35.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas CSTL's P/E ratio is -53.79. In terms of profitability, DGX's ROE is +0.14%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, DGX is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for DGX.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
DGX vs FLGT Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, FLGT has a market cap of 604.4M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while FLGT trades at $21.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas FLGT's P/E ratio is 2128.00. In terms of profitability, DGX's ROE is +0.14%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, DGX is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for DGX.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
DGX vs GRALV Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas GRALV's P/E ratio is N/A. In terms of profitability, DGX's ROE is +0.14%, compared to GRALV's ROE of N/A. Regarding short-term risk, DGX is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for DGX.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
DGX vs NEO Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, NEO has a market cap of 485.4M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while NEO trades at $19.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas NEO's P/E ratio is 145.31. In terms of profitability, DGX's ROE is +0.14%, compared to NEO's ROE of -0.06%. Regarding short-term risk, DGX is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for DGX.Check NEO's competition here
Global Cord Blood Corporation (NYSE: CO)
DGX vs CO Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas CO's P/E ratio is 5.06. In terms of profitability, DGX's ROE is +0.14%, compared to CO's ROE of +0.11%. Regarding short-term risk, DGX is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for DGX.Check CO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
DGX vs MYGN Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, MYGN has a market cap of 366.5M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while MYGN trades at $4.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas MYGN's P/E ratio is -29.85. In terms of profitability, DGX's ROE is +0.14%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, DGX is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for DGX.Check MYGN's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
DGX vs FLDM Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas FLDM's P/E ratio is -4.74. In terms of profitability, DGX's ROE is +0.14%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, DGX is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for DGX.Check FLDM's competition here
Prenetics Global Limited (NASDAQ: PRENW)
DGX vs PRENW Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, PRENW has a market cap of 277.8M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas PRENW's P/E ratio is N/A. In terms of profitability, DGX's ROE is +0.14%, compared to PRENW's ROE of -0.49%. Regarding short-term risk, DGX is less volatile compared to PRENW. This indicates lower risk in terms of short-term price fluctuations for DGX.Check PRENW's competition here
Biodesix, Inc. (NASDAQ: BDSX)
DGX vs BDSX Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, BDSX has a market cap of 225.5M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while BDSX trades at $28.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas BDSX's P/E ratio is -8.74. In terms of profitability, DGX's ROE is +0.14%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, DGX is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for DGX.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
DGX vs XGN Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, XGN has a market cap of 181M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while XGN trades at $7.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas XGN's P/E ratio is -9.25. In terms of profitability, DGX's ROE is +0.14%, compared to XGN's ROE of -1.22%. Regarding short-term risk, DGX is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for DGX.Check XGN's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
DGX vs IMDX Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, IMDX has a market cap of 129.8M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while IMDX trades at $3.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas IMDX's P/E ratio is -2.70. In terms of profitability, DGX's ROE is +0.14%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, DGX is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for DGX.Check IMDX's competition here
Genetron Holdings Limited (NASDAQ: GTH)
DGX vs GTH Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas GTH's P/E ratio is -1.11. In terms of profitability, DGX's ROE is +0.14%, compared to GTH's ROE of -1.01%. Regarding short-term risk, DGX is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for DGX.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
DGX vs GENE Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas GENE's P/E ratio is -38.25. In terms of profitability, DGX's ROE is +0.14%, compared to GENE's ROE of -1.85%. Regarding short-term risk, DGX is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for DGX.Check GENE's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
DGX vs SERA Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, SERA has a market cap of 76M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while SERA trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas SERA's P/E ratio is -3.06. In terms of profitability, DGX's ROE is +0.14%, compared to SERA's ROE of -0.47%. Regarding short-term risk, DGX is less volatile compared to SERA. This indicates lower risk in terms of short-term price fluctuations for DGX.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
DGX vs PRPO Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, PRPO has a market cap of 48.6M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while PRPO trades at $25.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas PRPO's P/E ratio is -104.77. In terms of profitability, DGX's ROE is +0.14%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, DGX is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for DGX.Check PRPO's competition here
MDxHealth S.A. (NASDAQ: MDXH)
DGX vs MDXH Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, MDXH has a market cap of 34.6M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while MDXH trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas MDXH's P/E ratio is -1.77. In terms of profitability, DGX's ROE is +0.14%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, DGX is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for DGX.Check MDXH's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
DGX vs QUCY Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, QUCY has a market cap of 30.5M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while QUCY trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas QUCY's P/E ratio is -0.06. In terms of profitability, DGX's ROE is +0.14%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, DGX is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for DGX.Check QUCY's competition here
Akumin Inc. (NASDAQ: AKU)
DGX vs AKU Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas AKU's P/E ratio is -0.13. In terms of profitability, DGX's ROE is +0.14%, compared to AKU's ROE of -5.32%. Regarding short-term risk, DGX is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for DGX.Check AKU's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
DGX vs CEMI Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas CEMI's P/E ratio is -0.63. In terms of profitability, DGX's ROE is +0.14%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, DGX is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for DGX.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
DGX vs ENZ Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas ENZ's P/E ratio is -2.24. In terms of profitability, DGX's ROE is +0.14%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, DGX is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for DGX.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
DGX vs PMD Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas PMD's P/E ratio is -5.24. In terms of profitability, DGX's ROE is +0.14%, compared to PMD's ROE of -0.32%. Regarding short-term risk, DGX is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for DGX.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
DGX vs ME Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas ME's P/E ratio is -0.03. In terms of profitability, DGX's ROE is +0.14%, compared to ME's ROE of -42.03%. Regarding short-term risk, DGX is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for DGX.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
DGX vs MYNZ Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, DGX's ROE is +0.14%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, DGX is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for DGX.Check MYNZ's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
DGX vs BNR Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, BNR has a market cap of 12.2M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while BNR trades at $13.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas BNR's P/E ratio is -13.29. In terms of profitability, DGX's ROE is +0.14%, compared to BNR's ROE of -0.13%. Regarding short-term risk, DGX is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for DGX.Check BNR's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
DGX vs ADVB Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, ADVB has a market cap of 11.2M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while ADVB trades at $8.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas ADVB's P/E ratio is -73.45. In terms of profitability, DGX's ROE is +0.14%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, DGX is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for DGX.Check ADVB's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
DGX vs CHEK Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas CHEK's P/E ratio is -0.43. In terms of profitability, DGX's ROE is +0.14%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, DGX is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for DGX.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
DGX vs CNTG Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas CNTG's P/E ratio is -0.23. In terms of profitability, DGX's ROE is +0.14%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, DGX is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for DGX.Check CNTG's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
DGX vs NDRA Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, NDRA has a market cap of 7.3M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while NDRA trades at $5.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas NDRA's P/E ratio is -0.73. In terms of profitability, DGX's ROE is +0.14%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, DGX is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for DGX.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
DGX vs APDN Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas APDN's P/E ratio is -0.10. In terms of profitability, DGX's ROE is +0.14%, compared to APDN's ROE of -7.23%. Regarding short-term risk, DGX is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for DGX.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
DGX vs NVTA Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas NVTA's P/E ratio is -0.00. In terms of profitability, DGX's ROE is +0.14%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, DGX is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for DGX.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
DGX vs LMDXW Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, DGX's ROE is +0.14%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, DGX is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for DGX.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
DGX vs LMDX Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas LMDX's P/E ratio is -0.01. In terms of profitability, DGX's ROE is +0.14%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, DGX is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for DGX.Check LMDX's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
DGX vs BIAFW Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, BIAFW has a market cap of 4.6M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while BIAFW trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas BIAFW's P/E ratio is 0.49. In terms of profitability, DGX's ROE is +0.14%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, DGX is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for DGX.Check BIAFW's competition here
DermTech, Inc. (NASDAQ: DMTK)
DGX vs DMTK Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas DMTK's P/E ratio is -0.04. In terms of profitability, DGX's ROE is +0.14%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, DGX is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for DGX.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
DGX vs NOTV Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas NOTV's P/E ratio is -0.03. In terms of profitability, DGX's ROE is +0.14%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, DGX is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for DGX.Check NOTV's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
DGX vs BIAF Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, BIAF has a market cap of 2.6M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while BIAF trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas BIAF's P/E ratio is -0.73. In terms of profitability, DGX's ROE is +0.14%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, DGX is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for DGX.Check BIAF's competition here
SeqLL Inc. (NASDAQ: SQL)
DGX vs SQL Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas SQL's P/E ratio is -0.40. In terms of profitability, DGX's ROE is +0.14%, compared to SQL's ROE of -30.46%. Regarding short-term risk, DGX is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for DGX.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
DGX vs AWH Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas AWH's P/E ratio is -0.09. In terms of profitability, DGX's ROE is +0.14%, compared to AWH's ROE of +1.62%. Regarding short-term risk, DGX is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for DGX.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
DGX vs HTGM Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas HTGM's P/E ratio is -0.03. In terms of profitability, DGX's ROE is +0.14%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, DGX is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for DGX.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
DGX vs BIOC Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas BIOC's P/E ratio is -0.01. In terms of profitability, DGX's ROE is +0.14%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, DGX is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for DGX.Check BIOC's competition here
iSpecimen Inc. (NASDAQ: ISPC)
DGX vs ISPC Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, ISPC has a market cap of 184.7K. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while ISPC trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas ISPC's P/E ratio is -0.04. In terms of profitability, DGX's ROE is +0.14%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, DGX is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for DGX.Check ISPC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
DGX vs SQLLW Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, DGX's ROE is +0.14%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, DGX is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for DGX.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
DGX vs WGSWW Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, DGX's ROE is +0.14%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, DGX is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for DGX.Check WGSWW's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
DGX vs MEUSW Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas MEUSW's P/E ratio is N/A. In terms of profitability, DGX's ROE is +0.14%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, DGX is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for DGX.Check MEUSW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
DGX vs NDRAW Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas NDRAW's P/E ratio is N/A. In terms of profitability, DGX's ROE is +0.14%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, DGX is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for DGX.Check NDRAW's competition here
Danaher Corporation (NYSE: DHR-PA)
DGX vs DHR-PA Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, DGX's ROE is +0.14%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, DGX is less volatile compared to DHR-PA. This indicates lower risk in terms of short-term price fluctuations for DGX.Check DHR-PA's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
DGX vs PRXL Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas PRXL's P/E ratio is 42.97. In terms of profitability, DGX's ROE is +0.14%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, DGX is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for DGX.Check PRXL's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
DGX vs OCDX Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas OCDX's P/E ratio is -42.28. In terms of profitability, DGX's ROE is +0.14%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, DGX is less volatile compared to OCDX. This indicates lower risk in terms of short-term price fluctuations for DGX.Check OCDX's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
DGX vs BNGOW Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas BNGOW's P/E ratio is N/A. In terms of profitability, DGX's ROE is +0.14%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, DGX is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for DGX.Check BNGOW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
DGX vs CHEKZ Comparison September 2026
Quest Diagnostics Incorporated (NYSE: DGX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 27.3B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, DGX is priced at $246.65 on the NYSE, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 24.39, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, DGX's ROE is +0.14%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, DGX is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for DGX.Check CHEKZ's competition here